|
Balance Sheet Cash Flow Statement 3280 Bayshore Blvd. Brisbane, CA 94005 CA Tel. 415-466-2200 Fax 415-466-2300 |
Type: Public
On the web:
http://www.intermune.com
Employees:
130
Employee growth: (1.5%)
InterMune has found a good thing in interferon gamma. The company's sole marketed product is Actimmune (interferon gamma-1b), an FDA-approved treatment for two rare congenital disorders: chronic granulomatous disease, an immune condition; and osteopetrosis, a disease causing abnormal bone growth. Most of Actimmune's sales, however, are for off-label use of the drug to treat the deterioration of lung function from scarring caused by idiopathic pulmonary fibrosis (IPF). InterMune is developing another potential IPF treatment called pirfenidone, and it is also researching hepatitis C therapies with Roche.
Key numbers for fiscal year ending December, 2008:
Sales: $48.2M
One year growth: (27.8%)
Net income: ($97.7)M
Officers:
Chairman, President, and CEO: Daniel G. (Dan) Welch
SVP Finance and Administration, and CFO: Biopharmaceuticals & Biotherapeutics
Competitors:
Actelion
Novartis
Schering-Plough
